 BALTIMORE--BUSINESS WIRE--Akers Biosciences, Inc. Nasdaq: AKER, today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. MyMD was issued US Pat. No. 10,835,523 B2, titled Method of Regulating Tumor Necrosis Factor-Alpha TNF-α for Treating Cancers, Autoimmune Disorders, and Other Disorders Associated with Chronic Inflammation by the United States Patent Trademark Office USPTO. The patent is a continuation of U.S. patent application No. 15558,094, which was 